

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM S-8

**REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933**

ALKERMES PUBLIC LIMITED COMPANY
(Exact name of registrant as specified in its charter)

Ireland

(State or other jurisdiction of incorporation or organization)

98-1007018

(I.R.S. Employer Identification No.)

**Connaught House
1 Burlington Road
Dublin 4, Ireland D04 C5Y6**
(Address of Principal Executive Offices)

ALKERMES PLC 2018 STOCK OPTION AND INCENTIVE PLAN, AS AMENDED
(Full title of the plan)

**David J. Gaffin, Esq.
Alkermes plc
Connaught House
1 Burlington Road
Dublin 4, Ireland D04 C5Y6**
(Name and address of agent for service)

Telephone: +353-1-772-8000
(Telephone number, including area code, of agent for service)

Please send copies of all communications to:

**Mitchell S. Bloom, Esq.
Robert E. Puopolo, Esq.**
Goodwin Procter LLP
100 Northern Avenue
Boston, MA 02210
Telephone: 617-570-1000

and

Christopher McLaughlin
Arthur Cox LLP, Ten Earlsfort Terrace, Dublin 2, D02 T380, Ireland
Telephone: +353 1 920 1000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒
Non-accelerated filer ☐

Accelerated filer ☐
Smaller reporting company ☐
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

EXPLANATORY NOTE

This registration statement on Form S-8 (this “Registration Statement”) is being filed for the purpose of registering an additional 5,900,000 ordinary shares, par value \$0.01 per share, of the Registrant (“Shares”) that may be issued pursuant to the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. The securities subject to this Registration Statement are of the same class of securities of the Registrant for which the Registrant previously filed registration statements on Form S-8 on February 16, 2012 (File No. 333-179545), October 26, 2012 (File No. 333-184621), December 5, 2014 (File No. 333-200777), December 7, 2016 (File No. 333-214952) and July 26, 2018 (File No. 333-226359), each amended by Post-Effective Amendment No. 1 filed by the Registrant on July 29, 2020, and registration statements on Form S-8 on July 25, 2019 (File No. 333-232831), July 29, 2020 (File No. 333-240170), July 28, 2021 (File No. 333-258229), July 27, 2022 (File No. 333-266350), July 26, 2023 (File No. 333-273456), July 24, 2024 (File No. 333-280984) and July 29, 2025 (File No. 333-289037) (collectively, the “Prior Registration Statements”). Accordingly, the contents of the Prior Registration Statements, as filed with the United States Securities and Exchange Commission (the “Commission”), are hereby incorporated by reference pursuant to General Instruction E to Form S-8.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

The following documents are hereby incorporated by reference into this Registration Statement (other than those portions of such documents that are furnished or otherwise not deemed to be filed):

- (i) The Registrant’s Annual Report on Form 10-K for the year ended [December 31, 2025](#);
- (ii) The Registrant’s Quarterly Reports on Form 10-Q for the quarters ended [March 31, 2026](#) and [June 30, 2026](#);
- (iii) The Registrant’s Current Reports on Form 8-K or Form 8-K/A filed with the Commission on [January 6, 2026](#), [February 12, 2026](#), [February 25, 2026](#), [May 1, 2026](#), [May 12, 2026](#), [May 20, 2026](#), [June 15, 2026](#) and [July 8, 2026](#) (excluding any portions of such Current Reports on Form 8-K that were furnished under Item 2.02 or Item 7.01 of Form 8-K and any exhibits related thereto); and
- (iv) The description of the Shares contained in the [“Description of Securities” filed as Exhibit 4.1](#) to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2025, including any amendment or report filed for the purpose of updating such description.

All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment which indicates that all securities offered herein have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing such documents. Any statement contained herein or in a document incorporated by reference or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that such statement is modified or superseded by any other subsequently filed document which is incorporated or is deemed to be incorporated by reference herein. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Item 4. Description of Securities.

Not applicable.

Item 5. Interests of Named Experts and Counsel.

Not applicable.

Item 6. Indemnification of Directors and Officers.

The Irish Companies Act 2014 permits a company to pay the costs or discharge the liability of a director or a secretary only where favorable judgment is given in any civil or criminal action in respect of such costs or liability, or where an Irish court grants relief because the director or secretary acted honestly and reasonably and ought fairly to be excused. This restriction does not apply to executives who are not directors or a secretary of the Registrant. Any provision by an Irish company which seeks to indemnify a

director or secretary of that Irish company over and above this shall be void under Irish law, whether contained in such company’s articles of association or any contract between the director or secretary and such company.

Pursuant to the Registrant’s articles of association, the Registrant will indemnify its current and former executives, any person who is serving or has served at the request of the Registrant as a director, executive or trustee of another company, joint venture, trust or other enterprise, and its directors and secretaries to the fullest extent permitted by law, against liabilities that are incurred by such executives, trustees, directors and secretaries while executing the duties of their respective offices. However, under the articles of association of the Registrant, unless the adjudicating court determines otherwise, such executives, trustees, directors and secretaries will not be entitled to indemnification by the Registrant if they are adjudged to be liable for fraud or dishonesty in the performance of their duties to the Registrant.

The current and certain former directors, secretaries and executive officers of the Registrant, and certain directors and officers of certain of the Registrant’s subsidiaries, including Alkermes, Inc., are entitled to be indemnified pursuant to indemnification agreements with the Registrant and/or Alkermes, Inc. Under the terms of these indemnification agreements, and subject to any conditions to indemnity set forth therein, (i) the Registrant and/or Alkermes, Inc., as applicable, indemnifies each relevant director, secretary, or officer to the maximum extent permitted by law for expenses and other amounts actually and reasonably incurred by or on behalf of the director, secretary, or officer in relation to claims brought against such director, secretary, or officer that arise from actions taken while acting as a director, secretary, or officer of the Registrant and/or its subsidiaries, except to the extent that such indemnification is prohibited by applicable law or would be duplicative of amounts otherwise actually provided to such director, secretary, or officer in relation to such claims; (ii) the Registrant and/or Alkermes, Inc. will, to the maximum extent permitted by law, advance the expenses of such director, secretary, or officer in connection with his or her defense and (iii) each director, secretary, or officer undertakes, to the fullest extent required by law, to repay all amounts advanced if and to the extent it is ultimately determined by a court of competent jurisdiction in a final judgment that he or she is not entitled to be indemnified by the Registrant and/or Alkermes, Inc., as applicable.

The Registrant has also obtained directors’ and officers’ liability insurance which insures its executives and directors against certain liabilities that such persons may incur in their capacities as officers and/or directors of the Registrant.

Item 7. Exemption from Registration Claimed.

Not applicable.

Item 8. Exhibits.

The following exhibits are filed as part of this Registration Statement:

Exhibit No.	Description of Exhibit
4.1	Memorandum and Articles of Association of Alkermes plc (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q filed on May 1, 2024 (File No. 001-35299)).
4.2	Alkermes plc 2018 Stock Option and Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on May 20, 2026 (File No. 001-35299)).
5.1*	Opinion of Arthur Cox LLP, Solicitors, as to the legality of the securities being registered.
23.1*	Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.
23.2*	Consent of Deloitte & Touche LLP, Avadel Pharmaceuticals plc’s Independent Auditor.
23.3*	Consent of Arthur Cox LLP, Solicitors (included in Exhibit 5.1 filed herewith).
24*	Power of Attorney (included in signature page).
107*	Filing Fee Table.

* Filed herewith.

Item 9. Undertakings.

(a) The undersigned Registrant hereby undertakes:

(1) to file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

- (i) to include any prospectus required by Section 10(a)(3) of the Securities Act;
- (ii) to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Filing Fee Table" in the effective registration statement; and
- (iii) to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

- (2) that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
- (3) to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

[THE NEXT PAGE IS THE SIGNATURE PAGE]

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Clarinbridge, Ireland, on July 28, 2026.

ALKERMES PLC

By: /s/ Tom Riordan

Name: Tom Riordan

Title: Assistant Company Secretary

POWER OF ATTORNEY AND SIGNATURES

We, the undersigned officers, directors and/or authorized representative in the United States of the Registrant hereby severally constitute and appoint Blair C. Jackson and Joshua Reed, and each of them, our true and lawful attorney-in-fact, with full power of substitution, to sign for us and in our names and the capacities indicated below, to execute and cause to be filed with the Securities and Exchange Commission any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, with exhibits thereto and all other documents in connection therewith, and generally to do or cause to be done by virtue hereof all things in our names and on our behalf in such capacities to enable the Registrant to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

SIGNATURE	TITLE	DATE
<u>/s/ Richard F. Pops</u> Richard F. Pops	Chairman and Chief Executive Officer (Principal Executive Officer)	July 28, 2026
<u>/s/ Joshua Reed</u> Joshua Reed	Senior Vice President, Chief Financial Officer (Principal Financial Officer and Authorized Representative in the U.S.)	July 28, 2026
<u>/s/ Samuel J. Parisi</u> Samuel J. Parisi	Vice President, Finance (Interim Principal Accounting Officer)	July 28, 2026
<u>/s/ Shane M. Cooke</u> Shane M. Cooke	Director	July 28, 2026
<u>/s/ Richard B. Gaynor</u> Richard B. Gaynor	Director	July 28, 2026
<u>/s/ Cato T. Laurencin</u> Cato T. Laurencin	Director	July 28, 2026
<u>/s/ Nancy S. Lurker</u> Nancy S. Lurker	Director	July 28, 2026
<u>/s/ Brian P. McKeon</u> Brian P. McKeon	Director	July 28, 2026
<u>/s/ Nancy L. Snyderman</u> Nancy L. Snyderman	Director	July 28, 2026
<u>/s/ Frank Anders Wilson</u> Frank Anders Wilson	Director	July 28, 2026
<u>/s/ Christopher I. Wright</u> Christopher I. Wright	Director	July 28, 2026

ARTHUR COX

28 July 2026

To: Board of Directors
Alkermes plc
Connaught House
Burlington Road
Dublin 4
Ireland D04 C5Y6

Re: Alkermes plc - registration statement on Form S-8 in relation to the Alkermes plc 2018 Stock Option and Incentive Plan, amended

Dear Sirs,

1. **Basis of Opinion**

- 1.1 We are acting as Irish counsel to Alkermes plc, registered number 498284, a public company limited by shares, incorporated under the laws of Ireland, with its registered office at Connaught House, 1 Burlington Road, Dublin 4, Ireland D04 C5Y6 (the “**Company**”), in connection with the registration statement on Form S-8 to be filed with the United States Securities and Exchange Commission (the “**SEC**”) on or about the date hereof (the “**Registration Statement**”) under the Securities Act of 1933, as amended (the “**Securities Act**”), with respect to an additional 5,900,000 ordinary shares with nominal value US\$0.01 per share of the Company (the “**Shares**”) that may be delivered pursuant to the Alkermes plc 2018 Stock Option and Incentive Plan, as amended (the “**Plan**”).
 - 1.2 This Opinion is confined to and given in all respects on the basis of the laws of Ireland (meaning Ireland exclusive of Northern Ireland) in force as at the date hereof as currently applied by the courts of Ireland. We have made no investigation of and we express no opinion as to the laws of any other jurisdiction or the effect thereof. In particular, we express no opinion on the laws of the European Union as they affect any jurisdiction other than Ireland. We have assumed without investigation that insofar as the laws of any jurisdiction other than Ireland are relevant, such laws do not prohibit and are not inconsistent with any of the obligations or rights expressed in the Plan Documents (as set out in the Schedule) (the “**Plan Documents**”) or the transactions contemplated thereby.
 - 1.3 This Opinion is also strictly confined to:
 - (a) the matters expressly stated herein at paragraph 2 below and is not to be read as extending by implication or otherwise to any other matter;
 - (b) the Plan Documents (as set out in the Schedule); and
 - (c) the Searches (as defined at 1.7 below),and is subject to the assumptions and qualifications set out below.
 - 1.4 We express no opinion, and make no representation or warranty, as to any matter of fact or in respect of any documents which may exist in relation to the Plan or the Shares other than the Plan Documents.
-

ARTHUR COX

- 1.5 In giving this Opinion, we have relied upon the Corporate Certificate (as defined in the Schedule to this Opinion) and the Searches and we give this Opinion expressly on the terms that no further investigation or diligence in respect of any matter referred to in the Corporate Certificate or the Searches is required of us.
- 1.6 For the purpose of giving this Opinion, we have examined and relied on copies sent to us by email in pdf or other electronic format of the Plan Documents.
- 1.7 For the purpose of giving this Opinion, we have caused to be made legal searches against the Company on 28 July 2026 (together the “**Searches**”):
- (a) on the file of the Company maintained by the Registrar of Companies in the Irish Companies Registration Office for mortgages, debentures or similar charges or notices thereof, and for the appointment of any examiner, receiver or liquidator;
 - (b) in the Judgments Office of the High Court for unsatisfied judgments, orders, decrees and the like for the five years immediately preceding the date of the search;
 - (c) in the Central Office of the High Court for any petitions filed in respect of the Company in the last two years; and
 - (d) in the Central Office of the High Court for any proceedings filed by or against the Company in the five years immediately preceding the date of the search.
- 1.8 This Opinion is governed by and is to be construed in accordance with the laws of Ireland as interpreted by the courts of Ireland at the date hereof. This Opinion speaks only as of its date. We assume no obligation to update this Opinion at any time in the future or to advise you of any change in law or change in interpretation of law which may occur after the date of this Opinion.

2. **Opinion**

Subject to the assumptions and qualifications set out in this Opinion and to any matters not disclosed to us, we are of the opinion that:

- 2.1 The Company is a public company limited by shares, is duly incorporated and validly existing under the laws of Ireland and has the requisite corporate authority to allot and issue the Shares.
- 2.2 When the Shares are allotted and issued (and, if required, paid for in cash) pursuant to and in accordance with the terms and conditions referred to or summarised in the applicable resolutions and the Plan, the Shares will be validly issued, fully paid up and non-assessable (which term means when used herein that no further sums are required to be paid by the holders thereof in connection with the allotment and issue of such Shares).

3. **Assumptions**

For the purpose of giving this Opinion, we assume the following without any responsibility on our part if any assumption proves to have been untrue as we have not verified independently any assumption:

ARTHUR COX

The Registration Statement and the Plan

- 3.1 that when filed with the SEC, the Registration Statement will not differ in any material respect from the latest draft that we have examined;
- 3.2 that any awards granted pursuant to the Plan will be paid up in consideration of the receipt by the Company prior to, or simultaneously with, the allotment and issue of the Shares pursuant thereto of cash at least equal to the nominal value of such Shares and any premium required to be paid up on the Shares pursuant to their terms of allotment and issue and that where Shares are allotted and issued under the Plan without the requirement for the payment of cash consideration by or on behalf of the relevant beneficiary, then such Shares shall either be fully paid up by the Company or one of its subsidiaries within the time permitted by section 1027(1) of the Companies Act 2014 (as amended) (the “**Companies Act**”) (and, in the case of the Company or a subsidiary incorporated in Ireland, in a manner permitted by sections 82(6) and 1043(1) of the Companies Act or allotted and issued for consideration as set out in section 1028(2) of the Companies Act);
- 3.3 that the filing of the Registration Statement with the SEC has been authorised by all necessary actions under all applicable laws (other than Irish law), including applicable U.S. federal and state securities laws;
- 3.4 that the exercise of any options and rights granted under the Plan and the allotment and issue of the Shares upon exercise of such options and rights (and the allotment and issue of the Shares in connection with any other awards granted under the Plan) will be conducted in accordance with the terms and the procedures described in the Plan and the applicable award agreement;
- 3.5 that at the time of the allotment and issuance of the Shares, such allotment and issuance shall not be in contravention or breach of any agreement, undertaking, arrangement, deed or covenant affecting the Company or to which the Company is a party or otherwise bound or subject;
- 3.6 that the Company has sufficient authorised but unissued share capital to allot and issue the required number of Shares to be delivered to the recipients of any awards granted under the Plan;
- 3.7 that, at the time of the allotment and issuance of the Shares, the authority of the Company and the directors of the Company to allot and issue the Shares, as provided for in the Companies Act and the Memorandum and Articles of Association of the Company, is in full force and effect and that the statutory pre-emption rights have been disapplied in respect of any allotment and issuance of the Shares;
- 3.8 that the Company will continue to renew its authority to allot and issue the Shares in accordance with the terms and conditions set out in the Memorandum and Articles of Association of the Company and the Companies Act and that, where such authority has not been renewed, the Company will not allot or issue the Shares after such authority has expired;
- 3.9 that from the date of the board resolutions set out in the Schedule, no other corporate or other action has been taken by the Company to amend, alter or repeal those resolutions;

ARTHUR COX

Authenticity and bona fides

- 3.10 the completeness and authenticity of all documents submitted to us as originals or copies of originals and (in the case of copies) conformity to the originals of copy documents and the genuineness of all signatories, stamps and seals thereon;
- 3.11 where incomplete Plan Documents have been submitted to us or signature pages only have been supplied to us for the purposes of issuing this Opinion, that the originals of such Plan Documents correspond in all respects with the last draft of the complete Plan Documents submitted to us;
- 3.12 that the Plan Documents will be executed in a form and content having no material difference to the drafts provided to us, will be delivered by the parties thereto, and that the terms thereof will be observed and performed by the parties thereto;
- 3.13 that the copies produced to us of minutes of meetings and/or of resolutions correctly record the proceedings at such meetings and/or the subject matter which they purport to record and that any meetings referred to in such copies were duly convened, duly quorate and held and all formalities were duly observed, that those present at any such meetings were entitled to attend and vote at the meeting and acted bona fide throughout and acted in accordance with their duties and that all resolutions set out in such copies were duly passed and that no further resolutions have been passed or corporate or other action taken which would or might alter the effectiveness thereof and that such resolutions have not been amended or rescinded and are in full force and effect;
- 3.14 that the Memorandum and Articles of Association of the Company amended on 13 May 2022 are the current Memorandum and Articles of Association of the Company, are up to date and have not been amended or superseded and that there are no other terms governing the Shares other than those set out in the Memorandum and Articles of Association of the Company;
- 3.15 that there is, at the relevant time of the allotment and issue of the Shares, no matter affecting the authority of the Directors to allot and issue the Shares, not disclosed by the Memorandum and Articles of Association of the Company or the resolutions produced to us, which would have any adverse implications in relation to the opinions expressed in this Opinion;

Accuracy of Searches and Warranties

- 3.16 the accuracy and completeness of the information disclosed in the Searches is accurate as of the date of this Opinion and that such information has not since the time of such search or enquiry been altered. It should be noted that:
 - (a) the matters disclosed in the Searches may not present a complete summary of the actual position on the matters we have caused searches to be conducted for;
 - (b) the position reflected by the Searches may not be fully up-to-date; and
 - (c) searches at the Companies Registration Office, Dublin, do not necessarily reveal whether or not a prior charge has been created or a resolution has been passed or a petition presented or any other action taken for the winding-up of or the appointment of a receiver or an examiner to the Company or its assets and accordingly, it is assumed that the Searches correctly reflect that:

ARTHUR COX

- (i) no receiver, liquidator or examiner or other similar officer has been appointed in relation to the Company or any of its assets or undertakings;
- (ii) no petition for the making or a winding-up order or the appointment of an examiner or any similar officer has been presented in relation to the Company;
- (iii) no insolvency proceedings have been opened or been requested to be opened in relation to the Company; and
- (iv) the Company is at the date of this Opinion able to pay its debts as they fall due within the meaning of Sections 509(3) and 570 of the Companies Act;

3.17 that there has been no alterations in the status or condition of the Company as disclosed by the Searches;

3.18 the truth, completeness and accuracy of all representations and statements as to factual matters contained in the Plan Documents;

Solvency and Insolvency

3.19 that:

- (a) the Company is at the date of this Opinion able to pay its debts within the meaning of Sections 509(3) and 570 of the Companies Act or any analogous provisions under any applicable laws; and
- (b) the Company will not, as a consequence of doing any act or thing which the Plan Documents contemplate, permit or require any relevant party to do, be unable to pay its debts within the meaning of such Sections or any analogous provisions under any applicable laws.

3.20 that:

- (a) no liquidator, receiver or examiner or other similar or analogous officer has been appointed in relation to the Company or any of the assets or undertakings; and
- (b) no petition for the making of a winding-up order or the appointment of an examiner or any similar officer or any similar or analogous procedure in any jurisdiction has been presented in relation to the Company.

Commercial Benefit

3.21 that the Plan Documents have been entered into for *bona fide* commercial purposes, on arm's length terms and for the benefit of each party thereto and are in those parties' respective commercial interests and for their respective corporate benefit.

4. **Disclosure**

This Opinion is addressed to you in connection with the registration of the Shares with the SEC. We hereby consent to the inclusion of this Opinion as an exhibit to the Registration Statement to be filed with the SEC. In giving this consent, we do not thereby admit that we are in a category of persons whose consent is required under Section 7 of the Securities Act.

ARTHUR COX

Yours faithfully,

/s/ Arthur Cox LLP

ARTHUR COX LLP

ARTHUR COX

SCHEDULE

The Plan Documents

1. A copy of the form of the Registration Statement to be filed by the Company with the SEC on or about the date of this Opinion;
2. a copy of the Plan;
3. a copy of the registration statement on Form S-8 (Registration Number 333-226359) filed on 26 July 2018;
4. a copy of the registration statement on Form S-8 (Registration Number 333-232831) filed on 25 July 2019;
5. a copy of the registration statement on Form S-8 (Registration Number 333-240170) filed on 29 July 2020 and Post-Effective Amendment No. 1 to registration statements on Form S-8 Nos. 333-179545, 333-184621, 333-200777, 333-214952 and 333-226359, filed on 29 July 2020;
6. a copy of the registration statement on Form S-8 (Registration Number 333-258229) filed on 28 July 2021;
7. a copy of the registration statement on Form S-8 (Registration Number 333-266350) filed on 27 July 2022;
8. a copy of the registration statement on Form S-8 (Registration Number 333-273456) filed on 26 July 2023;
9. a copy of the registration statement on Form S-8 (Registration Number 333-280984) filed on 24 July 2024;
10. a copy of the registration statement on Form S-8 (Registration Number 333- 289037) filed on 29 July 2025;
11. a copy of the resolutions of the board of directors of the Company delegating to the compensation committee of the board of directors of the Company the authority to approve, among other things, the Plan, dated 15-16 February 2018;
12. a copy of the resolutions of the compensation committee of the board of directors of the Company regarding the approval and adoption of, among other things, the Plan, dated 29 March 2018;
13. a copy of the resolutions of the board of directors of the Company approving, among other things, the preparation, execution and filing of a registration statement on Form S-8 (in respect of 4,400,000 ordinary shares with nominal value US\$0.01 per share of the Company (“**Ordinary Shares**”) under the Plan), dated 23-24 May 2018;
14. a copy of the resolutions of the board of directors of the Company delegating to the compensation committee of the board of directors of the Company the authority to approve a request for an amendment of, and increase in Ordinary Shares available under, the Plan, dated 13-14 February 2019;
15. a copy of the resolutions of the compensation committee of the board of directors of the Company regarding an amendment of, and increase in Ordinary Shares available under, the Plan, dated 28 March 2019;

ARTHUR COX

16. a copy of the resolutions of the board of directors of the Company that, among other things, gave authority for the preparation, execution and filing of a registration statement on Form S-8 (in respect of 5,200,000 Ordinary Shares under the Plan) at a meeting of the board of directors of the Company, dated 22-23 May 2019;
17. a copy of the resolutions of the board of directors of the Company delegating to the compensation committee of the board of directors of the Company the authority to approve a request for an additional increase in Ordinary Shares available under the Plan, dated 12 February 2020;
18. a copy of the resolutions of the compensation committee of the board of directors of the Company related to, among other things, an additional increase in the number of Ordinary Shares available under the Plan, dated 27 March 2020;
19. a copy of the resolutions of the board of directors of the Company that, among other things, gave authority for the preparation, execution and filing of a registration statement on Form S-8 and post-effective amendment to prior registration statements on Form S-8 (in respect of, in aggregate, such number of additional Ordinary Shares as were authorised for issuance under the amendment to the Plan approved at the annual general meeting of shareholders of the Company held on 20 May 2020 (the “**2020 AGM**”)) at a meeting of the board of directors of the Company dated 20 May 2020;
20. a copy of the resolutions of the board of directors of the Company delegating to the compensation committee of the board of directors of the Company the authority to approve a request for an amendment of, and increase in Ordinary Shares available under, the Plan, dated 10-11 February 2021;
21. a copy of the resolutions of the compensation committee of the board of directors of the Company regarding an amendment of, and increase in Ordinary Shares available under, the Plan, dated 15 March 2021;
22. a copy of the resolutions of the board of directors of the Company that, among other things, gave authority for the preparation, execution and filing of a registration statement on Form S-8 (in respect of 8,000,000 Ordinary Shares under the Plan), dated 18-19 May 2021;
23. a copy of the resolutions of the board of directors of the Company delegating to the compensation committee of the board of directors of the Company the authority to approve a request for an amendment of, and increase in Ordinary Shares available under, the Plan, dated 14-15 February 2022;
24. a copy of the resolutions of the compensation committee of the board of directors of the Company regarding an amendment of, and increase in Ordinary Shares available under, the Plan, dated 16 May 2022;
25. a copy of the resolutions of the board of directors of the Company that, among other things, gave authority for the preparation, execution and filing of a registration statement on Form S-8 (in respect of 8,300,000 Ordinary Shares under the Plan), dated 24-25 May 2022;
26. a copy of the resolutions of the board of directors of the Company delegating to the compensation committee of the board of directors of the Company the authority to approve a request for an amendment of, and increase in Ordinary Shares available under, the Plan, dated 15-16 February 2023;
27. a copy of the resolutions of the compensation committee of the board of directors of the Company regarding an amendment of, and increase in Ordinary Shares available under, the Plan, dated 3 April 2023;

ARTHUR COX

28. a copy of the resolutions of the board of directors of the Company that, among other things, gave authority for the preparation, execution and filing of a registration statement on Form S-8 (in respect of 6,500,000 Ordinary Shares under the Plan), dated 24-25 May 2023;
29. a copy of the resolutions of the board of directors of the Company delegating to the compensation committee of the board of directors of the Company the authority to approve a request for an amendment of, and increase in Ordinary Shares available under, the Plan, dated 14-15 February 2024;
30. a copy of the resolutions of the compensation committee of the board of directors of the Company regarding an amendment of, and increase in Ordinary Shares available under, the Plan, dated 2 April 2024;
31. a copy of the resolutions of the board of directors of the Company that, among other things, gave authority for the preparation, execution and filing of the Registration Statement in respect of the Shares under the Plan, dated 22-23 May 2024;
32. a copy of the resolutions of the board of directors of the Company delegating to the compensation committee of the board of directors of the Company the authority to approve a request for an amendment of, and increase in Ordinary Shares available under, the Plan, dated 11-12 February 2025;
33. a copy of the resolutions of the compensation committee of the board of directors of the Company regarding an amendment of, and increase in Ordinary Shares available under, the Plan, dated 26 March 2025;
34. a copy of the resolutions of the board of directors of the Company that, among other things, gave authority for the preparation, execution and filing of the Registration Statement in respect of the Shares under the Plan and approved the charter of the compensation committee of the board of directors of the Company, dated 21-22 May 2025;
35. a copy of the resolutions of the board of directors of the Company delegating to the compensation committee of the board of directors of the Company the authority to approve a request for an amendment of, and increase in Ordinary Shares available under, the Plan, dated 10-11 February 2026;
36. a copy of the resolutions of the compensation committee of the board of directors of the Company regarding an amendment of, and increase in Ordinary Shares available under, the Plan, dated 25 March 2026;
37. a copy of the resolutions of the board of directors of the Company that, among other things, gave authority for the preparation, execution and filing of a registration statement on Form S-8 (in respect of 5,900,000 Ordinary Shares under the Plan), dated 20-21 May 2026;
38. a corporate certificate of the Secretary of the Company dated 28 July 2026 (the “**Corporate Certificate**”) certifying, among other things: (A) the voting results regarding approval of: (i) the Plan by the shareholders of the Company at the annual general meeting of shareholders of the Company held on 23 May 2018, (ii) the Plan, as amended to increase the number of Ordinary Shares for issuance thereunder by 5,200,000 at the annual general meeting of shareholders of the Company held on 22 May 2019, (iii) the Plan, as amended to increase the number of Ordinary Shares for issuance thereunder by, in aggregate, such number of additional Ordinary Shares as were authorised for issuance under the Plan approved at the 2020 AGM, (iv) the Plan, as amended to increase the number of Ordinary Shares for issuance thereunder by 8,000,000 at the annual general meeting of shareholders of the Company held on 14 June 2021; (v) the Plan, as amended to increase the number of Ordinary Shares for issuance thereunder by 8,300,000 at the annual general meeting of shareholders of the Company held on 7 July 2022;

ARTHUR COX

(vi) the Plan, as amended to increase the number of Ordinary Shares for issuance thereunder by 6,500,000 at the annual general meeting of shareholders of the Company held on 29 June 2023; (vii) the Plan, as amended to increase the number of Ordinary Shares for issuance thereunder by 6,300,000, at the annual general meeting of shareholders of the Company held on 31 May 2024; (viii) the Plan, as amended to increase the number of Ordinary Shares for issuance thereunder by 4,250,000, being the Shares, at the annual general meeting of shareholders of the Company held on 21 May 2025; (ix) the Plan, as amended to increase the number of Ordinary Shares for issuance thereunder by 5,900,000, being the Shares, at the annual general meeting of shareholders of the Company held on 20 May 2026; and (B) the voting results regarding the approval of the granting of authority to the board of directors to allot shares of the Company up to an aggregate nominal amount of \$367,185 (36,718,501 shares) (being equivalent to approximately 20% of the aggregate nominal value of the issued ordinary share capital of the Company as of 1 April 2026); and to opt out of statutory pre-emption rights in respect of the allotment of equity securities up to an aggregate nominal value of \$367,185 (equivalent to 36,718,501 shares) (being equivalent to approximately 20% of the aggregate nominal value of the issued ordinary share capital of the Company as of 1 April 2026);

- 39. a copy of the memorandum and articles of association of the Company in the form adopted by resolution of the shareholders of the Company on 13 May 2022;
- 40. a copy of the certificate of incorporation of the Company dated 4 May 2011;
- 41. a copy of the certificate of incorporation on re-registration as a public limited company of the Company dated 25 July 2011;
- 42. a copy of the certificate of incorporation on change of name of the Company dated 14 September 2011; and
- 43. a letter of Status from the Irish Companies Registration Office dated 28 July 2026.

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Alkermes plc of our report dated February 25, 2026 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in Alkermes plc's Annual Report on Form 10-K for the year ended December 31, 2025.

/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
July 28, 2026

CONSENT OF INDEPENDENT AUDITORS

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 18, 2026 relating to the financial statements of Avadel Pharmaceuticals plc appearing in the Current Report on Form 8-K/A of Alkermes plc filed on May 1, 2026.

/s/ Deloitte & Touche LLP

St. Louis, Missouri
July 28, 2026

Alkermes plc.

	Security Type	Security Class Title	Fee Calculation Rule	Amount Registered	Proposed Maximum Offering Price Per Unit	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee
1	Equity	Ordinary Shares, par value \$0.01 per share	Other	5,900,000	\$ 52.14505	307,655,795.00	\$ 0.0001381	\$ 42,487.27
Total Offering Amounts:						\$ 307,655,795.00		\$ 42,487.27
Total Fee Offsets:								\$ 0.00
Net Fee Due:								\$ 42,487.27

1

Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), in addition to the Amount Registered, this registration statement shall also be deemed to cover an indeterminate number of additional ordinary shares, par value \$0.01 per share, of the Registrant ("Shares") which become issuable under the Alkermes plc 2018 Stock Option and Incentive Plan, as amended (the "2018 Plan") in the event that the number of outstanding Shares of the Registrant is increased by split-up, reclassification, stock dividend, recapitalization, or similar transactions. The Proposed Maximum Offering Price Per Unit and the Maximum Aggregate Offering Price have been estimated solely for the purpose of calculating the amount of the registration fee in accordance with Rules 457(c) and 457(h) of the Securities Act and based upon \$52.14505, the average of the high and low sale prices of the Shares as reported on the Nasdaq Global Select Market on July 21, 2026. The Amount Registered represents an increase to the number of Shares available for future issuance under the 2018 Plan. Shares currently available for issuance under the 2018 Plan were previously registered on prior registration statements filed with the United States Securities and Exchange Commission.

☒ Not Applicable[illegible]